Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program, with a total of 3,122,343 securities bought back before the previous day and an additional 119,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and neurodegenerative diseases. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: 6.32%
Average Trading Volume: 735,722
Technical Sentiment Signal: Buy
Current Market Cap: A$1.69B
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.